This page shows the latest Biktarvy news and features for those working in and with pharma, biotech and healthcare.
The drop was also partially offset by a 20% increase to $2.3bn from Biktarvy (bictegravir/emtricitabine/tenofovir) and Trodelvy (sacituzumab govitecan-hziy), said Gilead. ... The dynamics of the HIV treatment market further improved and this contributed
Overall, HIV product sales decreased by 12% to $3.7bn for the first quarter, although sales of its newer HIV treatment Biktarvy increased by 8% year-on-year in Q1.
Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) product.
ViiV’s rival Gilead was the first company to bring a single-tablet triple therapy – Biktarvy – to market, and the former has been desperately pushing its own two-drug oral therapies ... Gilead’s Biktarvy has grown quickly since its launch last
Taking aim at rival Biktarvy. ViiV Healthcare says it has data that shows people with HIV can safely switch from Gilead's three-drug therapies to one of its two-drug ... For comparison, Biktarvy brought in $739m in sales in the first quarter of the year,
Rivals Gilead's Biktarvy. ViiV Healthcare now has approval on both sides of the Atlantic for two-drug HIV therapy Dovato after a green light from the EMA. ... Dovato was approved in the US in April as a single-tablet, once-daily regimen for
More from news
Approximately 4 fully matching, plus 18 partially matching documents found.
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....